NephroPlus

Health Central recently published an article about recent progress and promising research in rare kidney diseases (RKDs). The article sheds light on clinical trials for different types of RKDs, new FDA rules for kidney medications, potential new treatments, and innovative research programs. It has shared information on three specific RKDs: immunoglobulin A nephropathy (IgAN), complement C3 glomerulopathy (C3G), and APOL1-mediated kidney disease (AMKD). 1. For immunoglobulin A nephropathy (IgAN), the FDA has given the drug sibeprenlimab "breakthrough therapy designation," showing its potential to reduce harmful IgA production in the kidneys. Several Phase 3 trials for IgAN treatments are in progress, including the BEYOND study testing the zigakibart drug. 2. For complement C3 glomerulopathy (C3G), Novartis' drug iptacopan has proven better than placebo in Phase 3 trials. 3. As for APOL1-mediated kidney disease (AMKD), which affects black individuals more often, a Phase 2 study of inaxaplin showed a 48% drop in urine protein levels, with a Phase 3 trial now recruiting participants. The article also introduces the Kidney Precision Medicine Project (KPMP), a collaborative effort across 22 institutions to create personalised treatments for specific kidney diseases. Breakthroughs like these can transform the lives of those affected by kidney diseases and NephroPlus sees such advancements as a stepping stone for kidney care. We are committed to supporting and integrating these innovations at our dialysis centres, enhancing the care we provide to our patients. Read more here: https://lnkd.in/d-8dnUzQ

Discover how animal companionship can transform the lives of dialysis guests. This blog explains how pets provide emotional support, improve physical health, enhance social interaction, and improve overall well-being. If you're undergoing dialysis or know someone who is, this blog will offer valuable insights on improving the quality of life through pets. Click on the link below to unlock the therapeutic power of animal companionship! https://lnkd.in/dgZymweH

The study by Mediwhale Inc. and Yonsei University College of Medicine shows that a new noninvasive test uses artificial intelligence (AI) and retinal scans to predict the risk of chronic kidney disease (CKD). Here are the most essential findings: 1. The test, called Reti-CKD, uses a deep learning algorithm to analyse retinal photographs and predict CKD risk. It outperforms conventional tests, such as estimated glomerular filtration rate (eGFR) or urine tests, in predicting future CKD risk. 2. The test is based on the similarity between retinal and kidney micro blood vessels, allowing retinal scans to indicate potential kidney issues. 3. This test can identify high-risk groups before kidney function declines, enabling preemptive measures. 4. The AI model was developed using data from over 79,000 Korean health checkups. 5. The test can stratify CKD risk into four classifications and accurately predict risk regardless of underlying conditions like hypertension or diabetes. 6. This non-invasive test offers a convenient and cost-effective solution that can be administered in primary care settings within minutes. The researchers aim to extend their study to predict kidney function deterioration among CKD patients and develop a model to pre-screen high-risk groups for end-stage chronic kidney disease. This breakthrough study represents a significant advancement in nephrology by showing how CKD is diagnosed and managed. The ability to accurately predict CKD risk can lead to earlier interventions, which is revolutionary in kidney treatment. Groundbreaking studies like the above are a testament to the fact that there is much to explore and innovate with regard to kidney care.  At NephroPlus, we are deeply committed to advancing kidney care through research and innovation. We aim to contribute to the development of better diagnostic tools, treatment options, and care protocols for kidney patients. We believe every contribution, be it through discussions, articles or clinical trials has the potential to improve patient outcomes and quality of life significantly. Read more here: https://lnkd.in/gbvujB2d

#hiring

The American Kidney Fund has shared an article discussing the promising results of a clinical trial investigating the effects of semaglutide on diabetic kidney disease. The trial shows that semaglutide, a glucagon-like peptide-1 (GLP-1) drug, has the potential to slow the progression of kidney disease and reduce the risk of death from kidney and heart disease in people with diabetic kidney disease. The drug is currently FDA-approved for blood sugar regulation in diabetes patients, weight loss for overweight or obese individuals, and reducing cardiovascular risks in certain adults. Novo Nordisk, a leading global healthcare company, began a clinical trial called the FLOW trial, which involved 3,553 participants from 28 countries with type 2 diabetes and kidney disease. The trial was divided into two groups and eventually stopped early due to positive efficacy results. It showed delayed progression of kidney disease and reduced risk of death from kidney and cardiovascular complications in the semaglutide group compared to the placebo group. However, semaglutide still needs to be FDA-approved for kidney disease treatment, and more detailed findings will be presented at a conference later this year. NephroPlus recently hosted a successful webinar featuring esteemed Indian nephrologists and researchers, focusing on the latest insights into Semaglutide and the FLOW trial. We are committed to creating spaces for discussions on cutting-edge research and contributing to advancements in kidney disease treatment in every way possible. Read more here: https://lnkd.in/dcQNruac

Your organs are a precious gift. Share the love by donating life. One day to go! Don’t miss this incredible opportunity to learn about the life-changing impact of living donor kidney transplantation. Join renowned experts Jaya Jairam and Anant Anekar as they delve into the intricacies of this selfless act. MOHAN Foundation Join- https://lnkd.in/gSPZhEak pwd=bpC8duNGa70OTbnMYwR7omx6mxyELn.1

Join us this Sunday as we deep dive into living donor kidney transplants! Join the webinar on the 18th of August through this link: https://lnkd.in/gHZAWfY4 MOHAN Foundation

This Independence Day, NephroPlus extends warm wishes to all. We're inspired by the resilience of our dialysis guests and everyone striving for better health. Today, let's celebrate our nation's freedom and renew our commitment to personal well-being.

Join our enlightening webinar on Living Donor Kidney Transplantation. Renowned experts, Jaya Jairam and Anant Anekar, will share invaluable insights into this life-saving procedure. From the decision-making process to post-transplant care, your questions will be answered. Don't miss this opportunity to learn from the best with MOHAN Foundation Register Now- https://lnkd.in/gHZAWfY4 #webinar #organdonation #nephroplus #dialysis #kidney

#hiring